CION Ameerpet
If you have searched ovarian cancer life expectancy, you have probably found a percentage and almost no explanation of what it measures. Those figures describe large groups of women diagnosed years ago — they are not a forecast for you, or for the person you are worried about. This page explains what each kind of number actually counts, so you can read one without it reading you.
Life expectancy is an actuarial idea. It answers a question about a population: how long, on average, does a large group of people live from a given starting point? It was never designed to answer the question you are actually asking, which is about one woman, with one stage, one tumour subtype, one surgical result and one response to treatment.
That mismatch is why oncologists sound evasive when asked for a number. Nobody has a table with your name in it. What exists instead is a set of group measures — five-year relative survival, median overall survival, progression-free survival — each counting something different, each calculated from women diagnosed several years before the figure was published, and each pooling together situations that behave nothing like one another.
That does not make the numbers useless. Read properly, they tell you which questions matter: what stage, which subtype, how much disease was removed, how the cancer responded to platinum-based chemotherapy. Read carelessly, a single percentage from a search result becomes a sentence handed down by nobody in particular. Understanding ovarian cancer statistics is mostly about knowing which of those two things is happening.
One more thing worth saying plainly at the start: ovarian cancer covers a very wide range of diseases. A young woman with a germ cell tumour and a woman of seventy with advanced high-grade serous cancer appear in the same national statistic and have almost nothing in common clinically. Any figure that has not been narrowed to your stage and subtype has already lost most of its meaning.
If a median survival is quoted, half the group lived longer than it — frequently far longer. A median is the middle of a spread, not a limit, and not a date.
Most published cancer survival is relative survival: it compares a diagnosed group with women of the same age in the general population, to strip out deaths from other causes.
Every figure you can find online was calculated across thousands of women. None of them was calculated for someone with your stage, subtype, surgery and general health.
In 1982 the palaeontologist Stephen Jay Gould was diagnosed with abdominal mesothelioma and read that the median survival for it was measured in months. Being a statistician by trade, he looked at the shape of the distribution rather than its midpoint — and saw that survival curves are strongly right-skewed: half the group lies above the median, and the tail on that side stretches for years. He lived a further two decades, and wrote the essay that oncologists still recommend to patients handed a number. The lesson is not that statistics are wrong. It is that a median describes the middle of a group, and says nothing about where in that group any individual sits. Source: Gould SJ, “The Median Isn’t the Message”, Discover (1985); NCI SEER Cancer Statistics methodology on relative survival.
If you are going to look the numbers up — and most people do — look them up properly. These are the six questions a specialist asks of any figure before letting it influence a decision.
Most survival statistics circulating in English come from American or European registries. They reflect that population's screening habits, referral pathways, access to specialist gynaecologic-oncology surgery and ability to complete a full course of treatment. Indian registry figures are collected differently, from a population that more often presents at an advanced stage.
Neither set is the truth about you. A figure from one health system applied to a woman in another is a rough analogy, not a measurement. Ask which registry a number came from before deciding what it means for a clinic in Hyderabad.
This is the least understood point and the most important. A five-year survival figure published this year cannot describe women treated this year — it describes women diagnosed at least five years ago, and usually longer once the registry lag is counted. The number is a photograph of the past.
Ovarian cancer treatment has changed inside that window. Routine BRCA and HRD testing, maintenance therapy after first-line chemotherapy, and better surgical selection all arrived after most published survival cohorts closed. A woman starting ovarian cancer treatment in Hyderabad today is not in that dataset, and could not have been.
Observed survival counts every death, whatever caused it. Relative survival compares the diagnosed group with women of the same age in the general population, which removes deaths from unrelated causes such as heart disease. The two figures for the same group can differ noticeably, particularly in older women.
Most headline cancer statistics are relative survival, and most articles quoting them do not say so. If a figure looks unusually low for an older age group, this is often the reason — you may be reading observed survival, which folds in every other cause of death alongside the cancer.
These are three different measures and they are routinely muddled. A median overall survival is the point at which half the group was still alive. A five-year survival rate is the proportion of a group alive at a fixed moment. A mean is rarely used in cancer statistics, precisely because the long tail distorts it.
The practical consequence: a median of any length is not a life expectancy, because a substantial part of the group lives well beyond it. When someone quotes a median as though it were a countdown, they have misread it.
A pooled ovarian cancer figure averages stage I disease found incidentally with stage IV disease spread through the abdomen. It also averages high-grade serous cancer with low-grade serous, mucinous, clear cell, endometrioid and germ cell tumours, which behave so differently that treating them as one disease makes the average meaningless for everybody in it.
Stage is the single strongest determinant, which is why the figures separate so dramatically once you split them. Our page on ovarian cancer survival by stage goes through what those splits do and do not settle.
Registry survival figures include every woman diagnosed, including those too unwell for surgery, those who declined treatment, those whose disease was found at a late complication, and those who never reached a specialist centre. That is the correct way to measure a health system, and a misleading way to estimate an individual outcome.
If you are fit enough for surgery, your disease was removed completely or near-completely, and you are able to complete platinum-based chemotherapy, you sit in a favourable part of that mixed group — not at its average. Nobody publishes a table for that subgroup, which is why a conversation with your own oncologist carries more information than the search result does.
None of these means the outlook is worse or better than you were told. Each is a reason to stop using a particular number and ask your own team for one that fits the situation.
A figure found online has no knowledge of your stage, subtype, grade or surgical outcome. Those four facts change the answer more than anything else does.
Published five-year figures were calculated before routine HRD testing and maintenance treatment. They cannot include a change that arrived after the cohort closed.
A germ cell tumour in a woman of 25 and high-grade serous cancer at 70 sit inside the same national number. An average across them describes neither.
An honest prognosis is a spread, not a point. A single figure with no range attached has usually been simplified for repetition rather than for accuracy.
A prognosis quoted before surgery, final histology and staging are done is provisional. It is worth revisiting once the pathology report is in front of you.
If a number is sitting heavily on you, bring it to a consultation and ask what it was measuring. In many cases the figure turns out to describe a group your situation does not belong to. Where the disease is advanced, our guide to living with advanced ovarian cancer deals with that conversation directly.
Bring the report, the scan or the figure someone quoted you. In 45 minutes a specialist can tell you what it describes, what it leaves out, and which parts of your own situation the published tables never accounted for.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
The first consultation is free and runs to 45 minutes. No referral needed, and no figure quoted at you without the context that makes sense of it.
Six figures get quoted interchangeably and mean entirely different things. This is ovarian cancer survival explained in the plainest terms we can manage — what each one counts, and where each one stops.
| The figure you have read | What it actually describes | What it cannot tell you |
|---|---|---|
| Five-year relative survival | The proportion of a diagnosed group still alive at five years, compared with women of the same age in the general population. | Anything about an individual, or what happens after year five — many women are alive and well far beyond it. |
| Median overall survival | The point in time at which half of a treated group was still alive. The other half lived longer, sometimes by years. | It is not a life expectancy and not a countdown. It says nothing about where in the spread any one woman sits. |
| Progression-free survival | How long treatment held the disease in check before it grew again. Used mainly to compare treatments in trials. | Not the same as survival. Disease that returns is treated again, and many women live for years after a first recurrence. |
| Conditional survival | The outlook recalculated from where you are now, for someone who has already reached this point in follow-up. | It is rarely quoted online, although it is usually the more useful figure once treatment is behind you. |
| One-year survival | A short-window measure used to compare services and centres, including the figure CION publishes for its own patients. | Too short a window to describe a long illness, and never a cure rate for anybody. |
| A single-centre or trial figure | The result in one hospital's patients, or among the carefully selected participants of a clinical trial. | Trial participants are fitter and more closely monitored than an average clinic population, so the figure travels badly. |
*Every figure above describes a group. None was calculated for a woman with your stage, subtype, surgical result and general health, which is why your treating team can put your situation in context in a way a published table never can. For what the stage-by-stage splits do and do not settle, see ovarian cancer survival by stage.
Most of the distress caused by survival statistics comes from reading them alone, at night, with nobody there to say which parts apply. A consultation fixes that faster than more reading does. Bring the report, the scan, or the figure a relative repeated to you, and ask what it was measuring.
Your first consultation at CION is free and runs to about 45 minutes — long enough to go through a pathology report line by line rather than summarise it. Every case is discussed at a tumour board rather than decided by one doctor, and we would rather give you an honest range with the reasoning behind it than a tidy number that is easier to repeat.
On what we do ourselves: medical oncology is delivered in-house. Platinum-based chemotherapy, maintenance therapy, genetic counselling with BRCA and HRD testing, nutrition support and long-term follow-up all happen at CION, across 35+ centres in Telangana and Andhra Pradesh. Debulking and other gynaecologic-oncology surgery is coordinated with specialist partner centres and may be billed there, as are HIPEC, intraperitoneal chemotherapy and PET-CT. We say so upfront rather than leaving it to be discovered at the billing counter.
One set of figures we do publish is our own. For ovarian cancer, 81.0% of CION patients are alive at one year, against a national figure of 73.7%. That is a one-year measure across everyone we treat — not a cure rate, and not a prediction for any individual. It is offered for the same reason as everything else on this page: a number is only worth quoting when what it counts is stated alongside it.
Free, unhurried and with a specialist. Long enough to read a pathology report together and explain what each line changes about the outlook.
Prognosis and treatment are discussed by medical oncology, imaging and pathology together, rather than settled by one clinician's impression.
Chemotherapy, maintenance therapy and genetic testing are in-house. Surgery, HIPEC and PET-CT are coordinated with specialist partner centres and may be billed there.
Chemotherapy and follow-up can be delivered near where you live, rather than requiring repeat journeys to a single city hospital.
*One-year survival rates. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups, not individuals — discuss your own outlook with your treating oncologist. Start with the complete ovarian cancer guide if the diagnosis is new.
There is no single honest answer to that question, and anyone who gives you one has skipped several steps. Ovarian cancer covers diseases that behave very differently: a germ cell tumour in a young woman, a low-grade serous cancer that grows over years, and advanced high-grade serous disease all sit inside the same phrase. Outlook depends on FIGO stage, tumour subtype and grade, how completely disease was removed at surgery, how the cancer responds to platinum-based chemotherapy, and general health. Those facts together tell your oncologist far more than any published figure does. What a specialist can give you is a considered range with the reasoning attached, revisited as staging, pathology and treatment response come in.
No, and confusing the two causes a great deal of unnecessary fear. A five-year survival rate is the proportion of a diagnosed group still alive at a fixed point five years on. It is not a prediction that anyone lives five years, and it is certainly not a limit. Most published cancer figures are relative survival, meaning the group is compared with women of the same age in the general population so that deaths from unrelated causes are stripped out. Life expectancy, by contrast, is an average lifespan for a population. Cancer statistics are not built that way, because the spread of outcomes is far too wide for an average to describe anybody in particular.
Because they measure different populations under different conditions. Registry figures reflect how early disease is found, how many women reach specialist gynaecologic-oncology surgery, whether complete cytoreduction is achieved, and how many are able to finish a full course of chemotherapy. Ovarian cancer in India is more often diagnosed at an advanced stage, which pulls the pooled figure down independently of how good the treatment is. Data collection also differs: registry coverage, follow-up completeness and the lag before publication are not the same. A figure from one health system applied to a woman in another is a rough analogy rather than a measurement, and it should not carry more weight than your own stage and pathology.
Generally not, and this is the most underappreciated limitation of any survival table. A five-year figure describes women diagnosed at least five years ago, and in practice longer once registry lag is counted. Several things that now shape ovarian cancer treatment arrived after most of those cohorts closed: routine BRCA and HRD testing, PARP-inhibitor-class maintenance therapy after first-line chemotherapy, anti-angiogenic treatment in selected cases, and better selection of who benefits from surgery first rather than chemotherapy first. None of that could be reflected in a number calculated before it existed. This is not a reason to assume the figures are wrong, only a reason to treat them as a photograph of the past rather than a forecast.
Yes, and this is where conditional survival becomes the more useful measure. Conditional survival recalculates the outlook for someone who has already reached a given point, and for most cancers it improves the further out you get, because the period of highest risk is behind you. That is a genuinely different question from the one a five-year figure answers on the day of diagnosis. It does not mean follow-up stops mattering: ovarian cancer can recur later than many cancers, so structured follow-up with clinical review and CA-125 continues on a planned schedule. But the number quoted at diagnosis is not the number that applies to you years later.
The first consultation is free and runs to about 45 minutes. CION delivers medical oncology for ovarian cancer in-house: platinum-based chemotherapy, maintenance therapy, genetic counselling with BRCA and HRD testing, nutrition support and long-term follow-up, across more than 35 centres in Telangana and Andhra Pradesh. Debulking and other gynaecologic-oncology surgery is coordinated with specialist partner centres and may be billed there, as are HIPEC, intraperitoneal chemotherapy and PET-CT. Every case is reviewed at a tumour board rather than decided by a single doctor. Bring your reports and any figure you have been given, and a specialist will go through what it measured and what it left out.